Arcutis Publications

Sort by:

Disease State

Conference

Sort by:

Conferences

European Academy of Dermatology and Venereology Spring Symposium 2021

Roflumilast Cream, a Once-Daily, Potent Phosphodiesterase-4 Inhibitor, in Chronic Plaque Psoriasis Patients: Efficacy and Safety From DERMIS-1 and DERMIS-2 Phase 3 Trials

PDF Icon.

American Academy of Dermatology 2021

The PASI-HD Improved Precision in Measuring Disease Severity in Subjects With Mild to Moderate Plaque Psoriasis Treated With Roflumilast Cream, a Phosphodiesterase-4 Inhibitor

PDF Icon.

Correlation of Itch Response to Roflumilast Cream With Disease Severity and Patient-Reported Outcomes in Patients With Chronic Plaque Psoriasis

PDF Icon.

Roflumilast Cream Significantly Improves Chronic Plaque Psoriasis in Patients With Steroid-Sensitive Area Involvement

PDF Icon.

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study

PDF Icon.

Once-Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Study

PDF Icon.

Innovations in Dermatology 2021

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

PDF Icon.

American Academy of Dermatology 2020

ARQ-151, Roflumilast Cream, Improved Psoriasis in Phase 2a Study

PDF Icon.

ARQ-151, Roflumilast Cream, Improved Chronic Plaque Psoriasis in Phase 2b Study

European Academy of Dermatology and Venereology 2020

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Listen to a brief summary of the phase 2b study of roflumilast cream in patients with atopic dermatitis

Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Symptom Burden in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Listen to a brief summary describing the improvements in patient burden observed in the phase 2b study of roflumilast cream in patients with psoriasis

Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Listen to a brief summary describing the improvements in itch observed in the phase 2b study of roflumilast cream in patients with psoriasis

The information contained in this website is intended for healthcare professionals (HCPs) only.



You are now leaving the Arcutis medical affairs website. Arcutis Biotherapeutics is not responsible for the content of linked sites.



Doximity social icon.
Doximity social icon.